Zdroje

This report presents the case for expanding the availability of blood plasma for the production of plasma-derived medicinal products for patients in all European countries, by growing local donations of plasma.

In collaboration with industry regulators and stakeholders, PPTA has developed a system that we believe is the best way to present the distribution of core plasma protein therapies in North America.

Be the first to know! Confidential Notification of Plasma Protein Therapy Withdrawals and Recalls The name says it all! The Patient Notification System (PNS) notifies the patient and all other registrants directly of a voluntary and/or mandated recall of plasma protein therapies. This makes all the difference — while other notification systems are designed to inform physicians and pharmacists, the PNS empowers the patient to receive this important information directly via email, telephone, text messaging, or fax. There is no charge to register.